Article 8U.K.Amendments to Decision 2010/712/EU

Decision 2010/712/EU is amended as follows:

1.

Article 1 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 4 600 000 for Spain;

(ii)

EUR 3 000 000 for Italy;

(iii)

EUR 90 000 for Cyprus;

(iv)

EUR 1 040 000 for Portugal;

(v)

EUR 1 350 000 for the United Kingdom.’;

(c)

in paragraph 3, points (a) to (d) are replaced by the following:

‘(a) for a rose bengal test

:

EUR 0,24 per test;

(b) for a SAT test

:

EUR 0,24 per test;

(c) for a complement fixation test

:

EUR 0,48 per test;

(d) for an ELISA test

:

EUR 1,2 per test’;

2.

Article 2 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 16 000 000 for Ireland;

(ii)

EUR 18 500 000 for Spain;

(iii)

EUR 5 500 000 for Italy;

(iv)

EUR 1 440 000 for Portugal;

(v)

EUR 26 500 000 for the United Kingdom.’;

(c)

in paragraph 3, points (a) and (b) are replaced by the following:

‘(a) for a tuberculin test

:

EUR 2,4 per test;

(b) for a gamma-interferon test

:

EUR 6 per test’;

3.

Article 3 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 160 000 for Greece;

(ii)

EUR 9 200 000 for Spain;

(iii)

EUR 4 200 000 for Italy;

(iv)

EUR 85 000 for Cyprus;

(v)

EUR 2 260 000 for Portugal.’;

(c)

in paragraph 3, points (a) and (b) are replaced by the following:

‘(a) for a rose bengal test

:

EUR 0,24 per test;

(b) for a complement fixation test

:

EUR 0,48 per test;’;

4.

Article 4 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 420 000 for Belgium;

(ii)

EUR 10 000 for Bulgaria;

(iii)

EUR 1 700 000 for the Czech Republic;

(iv)

EUR 0 for Denmark;

(v)

EUR 400 000 for Germany;

(vi)

EUR 10 000 for Estonia;

(vii)

EUR 10 000 for Ireland;

(viii)

EUR 100 000 for Greece;

(ix)

EUR 5 200 000 for Spain;

(x)

EUR 3 000 000 for France;

(xi)

EUR 300 000 for Italy;

(xii)

EUR 20 000 for Latvia;

(xiii)

EUR 5 000 for Lithuania;

(xiv)

EUR 60 000 for Hungary;

(xv)

EUR 10 000 for Malta;

(xvi)

EUR 50 000 for the Netherlands;

(xvii)

EUR 160 000 for Austria;

(xviii)

EUR 50 000 for Poland;

(xix)

EUR 1 650 000 for Portugal;

(xx)

EUR 100 000 for Romania;

(xxi)

EUR 50 000 for Slovenia;

(xxii)

EUR 60 000 for Slovakia;

(xxiii)

EUR 20 000 for Finland;

(xxiv)

EUR 20 000 for Sweden.’;

(c)

in paragraph 3, points (a) to (f) are replaced by the following:

‘(a) for an ELISA test

:

EUR 3 per test;

(b) for a PCR test

:

EUR 12 per test;

(c) for the purchase of monovalent vaccines

:

EUR 0,36 per dose;

(d) for the purchase of bivalent vaccines

:

EUR 0,54 per dose;

(e) for the administration of vaccines to bovine animals

:

EUR 1,80 per bovine animal vaccinated, regardless of the number and types of doses used;

(f) for the administration of vaccines to ovine or caprine animals

:

EUR 0,90 per ovine or caprine animal vaccinated, regardless of the number and types of doses used.’;

5.

Article 5 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 1 200 000 for Belgium;

(ii)

EUR 25 000 for Bulgaria;

(iii)

EUR 2 100 000 for the Czech Republic;

(iv)

EUR 340 000 for Denmark;

(v)

EUR 1 000 000 for Germany;

(vi)

EUR 40 000 for Estonia;

(vii)

EUR 120 000 for Ireland;

(viii)

EUR 1 000 000 for Greece;

(ix)

EUR 1 300 000 for Spain;

(x)

EUR 660 000 for France;

(xi)

EUR 1 700 000 for Italy;

(xii)

EUR 150 000 for Cyprus;

(xiii)

EUR 1 650 000 for Latvia;

(xiv)

EUR 20 000 for Luxembourg;

(xv)

EUR 2 400 000 for Hungary;

(xvi)

EUR 150 000 for Malta;

(xvii)

EUR 3 900 000 for the Netherlands;

(xviii)

EUR 1 200 000 for Austria;

(xix)

EUR 4 800 000 for Poland;

(xx)

EUR 65 000 for Portugal;

(xxi)

EUR 500 000 for Romania;

(xxii)

EUR 120 000 for Slovenia;

(xxiii)

EUR 600 000 for Slovakia;

(xxiv)

EUR 75 000 for the United Kingdom.’;

(c)

in paragraph 3, points (a) to (e) are replaced by the following:

‘(a) for a bacteriological test (cultivation/isolation)

:

EUR 8,4 per test;

(b) for the purchase of vaccine

:

EUR 0,06 per dose;

(c) for serotyping of relevant isolates of Salmonella spp.

:

EUR 24 per test;

(d) for a bacteriological test to verify the efficiency of disinfection of poultry houses after depopulation of a salmonella-positive flock

:

EUR 6 per test;

(e) for a test for the detection of antimicrobials or bacterial growth inhibitory effect in tissues from birds from flocks tested for salmonella

:

EUR 6 per test.’;

6.

Article 6 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 120 000 for Bulgaria;

(ii)

EUR 1 600 000 for Germany;

(iii)

EUR 240 000 for France;

(iv)

EUR 160 000 for Italy;

(v)

EUR 700 000 for Hungary;

(vi)

EUR 700 000 for Romania;

(vii)

EUR 30 000 for Slovenia;

(viii)

EUR 300 000 for Slovakia.’;

(c)

in paragraph 3, ‘EUR 2,5’ is replaced by ‘EUR 3’;

7.

Article 8 is amended as follows:

(a)

in paragraph 2(b), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(c) is replaced by the following:

‘(c)

shall not exceed the following:

(i)

EUR 90 000 for Belgium;

(ii)

EUR 25 000 for Bulgaria;

(iii)

EUR 70 000 for the Czech Republic;

(iv)

EUR 80 000 for Denmark;

(v)

EUR 300 000 for Germany;

(vi)

EUR 10 000 for Estonia;

(vii)

EUR 75 000 for Ireland;

(viii)

EUR 50 000 for Greece;

(ix)

EUR 150 000 for Spain;

(x)

EUR 150 000 for France;

(xi)

EUR 1 000 000 for Italy;

(xii)

EUR 20 000 for Cyprus;

(xiii)

EUR 45 000 for Latvia;

(xiv)

EUR 10 000 for Lithuania;

(xv)

EUR 10 000 for Luxembourg;

(xvi)

EUR 360 000 for Hungary

(xvii)

EUR 20 000 for Malta;

(xviii)

EUR 360 000 for the Netherlands;

(xix)

EUR 60 000 for Austria;

(xx)

EUR 100 000 for Poland;

(xxi)

EUR 45 000 for Portugal;

(xxii)

EUR 180 000 for Romania;

(xxiii)

EUR 50 000 for Slovenia;

(xxiv)

EUR 15 000 for Slovakia;

(xxv)

EUR 25 000 for Finland;

(xxvi)

EUR 50 000 for Sweden;

(xxvii)

EUR 160 000 for the United Kingdom.’;

(c)

in paragraph 3, points (a) to (e) are replaced by the following:

‘(a) ELISA test

:

EUR 2,4 per test;

(b) agar gel immune diffusion test

:

EUR 1,44 per test;

(c) HI test for H5/H7

:

EUR 14,40 per test;

(d) virus isolation test

:

EUR 48 per test;

(e) PCR test

:

EUR 24 per test.’;

8.

Article 9 is amended as follows:

(a)

in paragraph 2(c), ‘50 %’ is replaced by ‘60 %’;

(b)

paragraph 2(d) is replaced by the following:

‘(d)

shall not exceed the following:

(i)

EUR 1 900 000 for Belgium;

(ii)

EUR 330 000 for Bulgaria;

(iii)

EUR 1 030 000 for the Czech Republic;

(iv)

EUR 1 370 000 for Denmark;

(v)

EUR 7 750 000 for Germany;

(vi)

EUR 330 000 for Estonia;

(vii)

EUR 4 000 000 for Ireland;

(viii)

EUR 2 000 000 for Greece;

(ix)

EUR 6 650 000 for Spain;

(x)

EUR 18 850 000 for France;

(xi)

EUR 6 000 000 for Italy;

(xii)

EUR 1 700 000 for Cyprus;

(xiii)

EUR 320 000 for Latvia;

(xiv)

EUR 720 000 for Lithuania;

(xv)

EUR 125 000 for Luxembourg;

(xvi)

EUR 1 180 000 for Hungary;

(xvii)

EUR 25 000 for Malta;

(xviii)

EUR 3 530 000 for the Netherlands;

(xix)

EUR 1 800 000 for Austria;

(xx)

EUR 3 440 000 for Poland;

(xxi)

EUR 1 800 000 for Portugal;

(xxii)

EUR 1 000 000 for Romania;

(xxiii)

EUR 250 000 for Slovenia;

(xxiv)

EUR 550 000 for Slovakia;

(xxv)

EUR 580 000 for Finland;

(xxvi)

EUR 850 000 for Sweden;

(xxvii)

EUR 6 500 000 for the United Kingdom.’;

(c)

in paragraph 3(d) ‘EUR 10’ is replaced by ‘EUR 12’;

9.

Article 10, paragraph 2(c) is amended as follows:

(a)

in point (i) ‘EUR 1 800 000’ is replaced by ‘EUR 850 000’;

(b)

in point (ii) ‘EUR 620 000’ is replaced by ‘EUR 570 000’;

(c)

in point (iv) ‘EUR 7 110 000’ is replaced by ‘EUR 8 110 000’;

(d)

in point (v) ‘EUR 5 000 000’ is replaced by ‘EUR 2 100 000’;

(e)

in point (vii) ‘EUR 200 000’ is replaced by ‘EUR 290 000’;

10.

in Article 10 paragraph 4, ‘paragraphs 2 and 3’ is replaced by ‘paragraph 2(a), paragraph 2(b) and paragraph 3’;

11.

Article 11, paragraph 5(c) is amended as follows:

(a)

in point (i) ‘EUR 2 250 000’ is replaced by ‘EUR 1 600 000’;

(b)

in point (ii) ‘EUR 1 800 000’ is replaced by ‘EUR 1 500 000’;

(c)

in point (v) ‘EUR 740 000’ is replaced by ‘EUR 850 000’;

12.

in Article 11 paragraph 7, ‘paragraphs 5 and 6’ is replaced by ‘paragraph 5(a), paragraph 5(b) and paragraph 6’.